<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tetracycline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tetracycline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tetracycline: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9986" href="/d/html/9986.html" rel="external">see "Tetracycline: Drug information"</a> and <a class="drug drug_patient" data-topicid="11881" href="/d/html/11881.html" rel="external">see "Tetracycline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1050206"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Acne Products</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Ophthalmic</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Tetracycline Derivative</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Topical</span></li></ul></div>
<div class="block dop drugH1Div" id="F226328"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b>Children ≥8 years and Adolescents: Oral: 6.25 to 12.5 mg/kg/dose 4 times daily; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris (moderate to severe, inflammatory): Note:</b> Use as an adjunct to topical acne therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-23637225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years and Adolescents: Oral: 500 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80934a0b-eaaa-4956-92e4-5cbc87124c0c">
<i>Balantidium coli</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Balantidium coli </i>infection:</b> Children ≥8 years and Adolescents: Oral: 10 mg/kg/dose 4 times daily for 10 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-CDC.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="291da3f6-4546-4769-b192-f22ead1b5b60">Malaria, uncomplicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, uncomplicated, treatment:</b> Children ≥8 years and Adolescents: Oral: 6.25 mg/kg/dose 4 times daily for 7 days; maximum dose: 250 mg/dose. Use in combination with quinine sulfate (quinine sulfate duration is region/species specific). <b>Note:</b> If used for <i>Plasmodium vivax</i> or <i>Plasmodium ovale</i>, use this regimen in combination with primaquine for antirelapse treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27c158d1-f522-4d2c-a14b-8b661d97b007">Syphilis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syphilis (penicillin-allergic patients): Note:</b> Data to support the use of alternatives to penicillin are limited; close serologic and clinical follow up is warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 500 mg 4 times daily. Treat early syphilis (primary, secondary, and early latent) for 14 days and late latent syphilis or latent syphilis of unknown duration for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192965"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥8 years and Adolescents: There are no specific dosage adjustments provided in the manufacturer's labeling; decrease dose and/or extend dosing interval.</p></div>
<div class="block dohp drugH1Div" id="F51192966"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F226313"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9986" href="/d/html/9986.html" rel="external">see "Tetracycline: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b>
<b>Oral:</b> 250 to 500 mg 4 times daily or 500 mg twice daily.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c4354e0-2178-427d-a042-9beb609e2523">Acne vulgaris, inflammatory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, inflammatory, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use in combination with topical acne therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg twice daily. Treatment should ideally be limited to 3 to 4 months to minimize the risk of resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-Graber.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-Graber.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7130fea1-030c-4496-822e-505264056ed4">Cholera, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholera (<i>Vibrio cholerae</i>), treatment (adjunctive therapy for severely ill patients):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to resistance concerns, antimicrobial therapy during an outbreak or epidemic should be guided by local isolate susceptibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg 4 times daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8736618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8736618'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori </i>eradication (off-label use):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bismuth quadruple regimen</i>: <b>Oral:</b> 500 mg 4 times daily, in combination with standard-dose proton pump inhibitor twice daily, metronidazole 250 mg 4 times daily or 500 mg 3 or 4 times daily, and either bismuth subcitrate 120 to 300 mg 4 times daily or bismuth subsalicylate 300 to 524 mg 4 times daily; continue regimen for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-27102658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-27102658'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1a5c771-d06c-4f42-a40c-2a0c6db81cba">Hidradenitis suppurativa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa (off-label use): Oral:</b> 500 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9843011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9843011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8766acfb-a2c1-4ac2-b4a3-ffdf831de51e">Malaria, treatment, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, treatment, uncomplicated (alternative agent) (off-label use):</b>
<b>Oral:</b> 250 mg 4 times daily for 7 days with quinine sulfate (quinine sulfate duration is region specific). <b>Note:</b> If used for <i>Plasmodium</i>
<i> vivax</i> or <i>Plasmodium</i>
<i> ovale</i>, use this regimen in combination with primaquine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61b094d2-b7f7-4053-a315-b3a3e4e76280">Pityriasis lichenoides chronica</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pityriasis lichenoides chronica (off-label use): Oral:</b> 500 mg 4 times daily until lesions subside, followed by 250 mg 4 times daily for ≥1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4154770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4154770'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague </b>
<b>(</b>
<i>
<b>Yersinia pestis</b></i>
<b>) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis: </i>
<b>Oral: </b>500 mg every 6 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, bubonic or pharyngeal:</i>
<b>Oral:</b> 500 mg every 6 hours for 10 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Stout.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Stout.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8007b13-1f37-4f88-af43-7a90f40e7074">Rosacea, moderate to severe or unresponsive to topical therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rosacea, moderate to severe or unresponsive to topical therapy (off-label use): Oral:</b> 250 to 500 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26280139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26280139'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27c158d1-f522-4d2c-a14b-8b661d97b007">Syphilis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Syphilis (alternative agent for nonpregnant patients with penicillin allergy): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limited data support use of tetracycline as an alternative to penicillin, and close serologic and clinical follow-up is warranted; some experts prefer other alternative agents (eg, ceftriaxone, doxycycline) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Hicks.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Hicks.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Early syphilis (primary, secondary, and early latent [&lt;1-year duration]):</i>
<b>Oral:</b> 500 mg 4 times daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Late latent syphilis (&gt;1-year duration):</i>
<b>Oral:</b> 500 mg 4 times daily for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf64d97c-215c-415e-9c7b-86a9dd06850a">Tularemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tularemia (<i>Francisella tularensis</i>) (mild):</b>
<b>Oral:</b> 500 mg 4 times daily for at least 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990271"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer’s labeling:</i> There are no specific dosage adjustments provided in the manufacturer’s labeling; decrease dose and/or extend dosing interval.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternative dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</i>
<b>Note:</b> Renally adjusted dose recommendations are based on doses of 250 mg to 500 mg twice daily to 4 times daily.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute: Administer recommended dose based on indication every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR 10 to 50 mL/minute: Administer recommended dose based on indication every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute: Administer recommended dose based on indication every 24 hours.</p></div>
<div class="block doha drugH1Div" id="F50987474"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F226275"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pericarditis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythematous rash, maculopapular rash, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, <i>Clostridioides difficile</i>-associated diarrhea, diarrhea, dysphagia, enterocolitis, epigastric discomfort, glossitis, melanoglossia, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Inflammatory anogenital lesion (with monilial overgrowth)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Henoch-Schonlein purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Serum sickness-like reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Exacerbation of systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, nail discoloration (Demers 1968), onycholysis (Demers 1968)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Microscopic thyroid discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Discoloration of permanent tooth (infants, young children) (Demers 1968), dysgeusia (Syed 2016), enamel hypoplasia (infants, young children) (Demers 1968), esophageal ulcer (Channer 1981), esophagitis (Agha 1986), pancreatitis (Torosis 1987)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Balanitis (Dodds 1985)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia (Lehrner 1979), eosinophilia, hemolytic anemia, immune thrombocytopenia, neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and angioedema) (Ogita 2011; Steinbruegge 1980), nonimmune anaphylaxis (Barnett 1967)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hypertension (Walters 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Abnormal bone growth (fibula; premature infants) (Demers 1968), lupus-like syndrome (Lee 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival discoloration (bulbar pigment deposits) (Morrison 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (Pothier 1966)</p></div>
<div class="block coi drugH1Div" id="F226291"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to any of the tetracyclines or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe liver disease; severe renal disease; use in children &lt;12 years of age for therapy of common infections or conditions where bactericidal effect is essential (bacterial endocarditis); surgical prophylaxis; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F226272"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Increased BUN: May be associated with increases in serum urea nitrogen (BUN) secondary to antianabolic effects; use caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intracranial hypertension (eg, pseudotumor cerebri): Intracranial hypertension (headache, blurred vision, diplopia, vision loss, and/or papilledema) has been associated with use. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Concomitant use of isotretinoin (known to cause pseudotumor cerebri [PTC]) and tetracycline should be avoided. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patients until they stabilize.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Hepatotoxicity has been reported rarely; risk may be increased in patients with preexisting hepatic or renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May cause tissue hyperpigmentation, enamel hypoplasia, or permanent tooth discoloration; use of tetracyclines should be avoided during tooth development (children &lt;8 years of age) unless other drugs are not likely to be effective or are contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Acne: The American Academy of Dermatology acne guidelines recommend tetracycline as adjunctive treatment for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Concomitant topical therapy with benzoyl peroxide or a retinoid should be administered with systemic antibiotic therapy (eg, tetracycline) and continued for maintenance after antibiotic course is completed (AAD [Zaenglein 2016]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878649"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Do not use in patients &lt;8 years of age, unless other drugs are not likely to be effective or are contraindicated, due to potential for permanent discoloration of teeth (yellow, gray, or brown); enamel hypoplasia has also been reported. Effects are more common with long-term use, but may be observed with repeated, short courses.</p>
<p style="text-indent:0em;margin-top:2em;">Bone growth suppression, as evidenced by a decrease in the fibular growth rate, has been reported in premature infants treated with tetracycline; growth restriction up to 40% has been associated with oral tetracycline therapy but is reversible when short-term treatment is discontinued. Tetracycline binds to calcium in growing bones and negatively affects calcium orthophosphate metabolism; doses of 25 mg/kg/dose every 6 hours have resulted in restricted bone growth in premature infants. Upon discontinuation of tetracycline, rapid compensatory bone growth is observed (Cohlan 1963; Cross 2016; Wormser 2019).</p></div>
<div class="block foc drugH1Div" id="F226284"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F226268"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F226293"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Tetracycline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $7.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $15.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868381"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block exp drugH1Div" id="F10806665"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>25 mg/mL Oral Suspension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">A 25 mg/mL oral suspension may be made using capsules. Empty the contents of six 500 mg capsules into mortar. Add a small amount (~20 mL) of a 1:1 mixture of Ora-Sweet and Ora-Plus and mix to a uniform paste; mix while adding the vehicle in geometric proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well" and "refrigerate". Stable 28 days refrigerated.</p>
<div class="reference">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52613914"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach (ie, 1 hour before or 2 hours after meals) to increase total absorption; give with adequate amounts of fluid to reduce risk of esophageal irritation and ulceration.</p></div>
<div class="block adm drugH1Div" id="F226288"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer on an empty stomach (ie, 1 hour prior to, or 2 hours after meals) to increase total absorption and with adequate amount of fluid to reduce risk of esophageal irritation and ulceration. Administer at least 1 to 2 hours prior to, or 4 hours after antacid because aluminum and magnesium cations may chelate with tetracycline and reduce its total absorption.</p></div>
<div class="block sts drugH1Div" id="F226302"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); protect from light. Use of outdated tetracyclines has caused a Fanconi-like syndrome (nausea, vomiting, acidosis, proteinuria, glycosuria, aminoaciduria, polydipsia, polyuria, hypokalemia). </p></div>
<div class="block usep drugH1Div" id="F53569068"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of susceptible respiratory tract infections, skin and soft tissue infections, urinary tract infections, rickettsial infections, psittacosis, granuloma inguinale, relapsing fever, bartonellosis, chancroid, tularemia, plague, cholera, brucellosis, and infections caused by <i>Chlamydia trachomatis, Campylobacter fetus, </i>and susceptible gram-negative bacteria; adjunctive therapy in intestinal amebiasis and severe acne; alternative treatment (when penicillin is contraindicated) of syphilis, yaws, Vincent infection, anthrax, actinomycosis, and infections caused by <i>Neisseria gonorrhoeae, Listeria monocytogenes, </i>and <i>Clostridium </i>spp. (All indications: FDA approved in ages ≥8 years and adults). Has also been used for treatment of malaria and <i>Balantidium coli</i> infection.</p></div>
<div class="block mst drugH1Div" id="F226346"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tetracycline may be confused with tetradecyl sulfate</p>
<p style="text-indent:-2em;margin-left:4em;">Achromycin may be confused with actinomycin, Adriamycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Tetracycline, when used in neonates, infants, and children &lt;8 years of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list. In neonates, tetracycline should be used with caution due to risk of retardation of skeletal development and bone growth in premature neonates (strong recommendation; moderate quality of evidence); in infants and children &lt;8 years of age, it should be used with caution due to risk of tooth discoloration and enamel hypoplasia (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F226334"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F226277"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hours when possible to minimize the extent of this potential interaction. Monitor for decreased therapeutic effects of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atovaquone: Tetracycline (Systemic) may decrease the serum concentration of Atovaquone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: Tetracyclines may decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines.  Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Tetracyclines may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. If coadministration cannot be avoided, administer the polyvalent cation-containing multivitamin at least 2 hours before or 4 hours after the tetracycline derivative. Monitor for decreased tetracycline effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines cannot be avoided, administer the polyvalent cation-containing multivitamin either 2 hours before or 4 hours after the tetracycline product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Tetracyclines. Management: Give oral tetracyclines at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinapril: May decrease the serum concentration of Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: Tetracycline (Systemic) may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer most tetracycline derivatives at least 2 hours prior to sucralfate in order to minimize the impact of this interaction. Administer oral omadacycline 4 hours prior to sucralfate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 hour before sucroferric oxyhydroxide. Specific dose separation guidelines for other tetracyclines are not presently available. No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Tetracyclines may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zinc Salts: May decrease the absorption of Tetracyclines. Only a concern when both products are administered orally. Management: Separate administration of oral tetracycline derivatives and oral zinc salts by at least 2 hours to minimize this interaction.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F226303"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Serum concentrations may be decreased if taken with dairy products. Management: Take on an empty stomach 1 hour before or 2 hours after meals to increase total absorption. Administer around-the-clock to promote less variation in peak and trough serum levels.</p></div>
<div class="block dic drugH1Div" id="F9626655"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take on an empty stomach (ie, 1 hour prior to, or 2 hours after meals). Take at least 1-2 hours prior to, or 4 hours after antacid.</p></div>
<div class="block pri drugH1Div" id="F226294"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tetracycline crosses the placenta (Leblanc 1967).</p>
<p style="text-indent:0em;margin-top:2em;">Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of tetracycline are not altered in pregnant patients with normal renal function (Whalley 1966; Whalley 1970). Hepatic toxicity during pregnancy, potentially associated with tetracycline use, has been reported. Pregnant patients with renal disease may be more likely to develop hepatic failure with tetracycline use.</p>
<p style="text-indent:0em;margin-top:2em;">As a class, tetracyclines are generally considered second-line antibiotics in pregnant patients and their use should be avoided (Mylonas 2011). Many guidelines consider use of tetracycline to be contraindicated during pregnancy, or to be a relative contraindication in pregnant patients if other agents are available and appropriate for use (CDC 2020a; CDC [Anderson 2013]; IDSA [Stevens 2014]). When systemic antibiotics are needed for acne or dermatologic conditions in pregnant patients, other agents are preferred (AAD [Zaenglein 2016]; Murase 2014). Tetracycline may be used as an alternative antibiotic for pre- and post-exposure prophylaxis in pregnant patients exposed to <i>Y. pestis </i>(CDC [Nelson 2021]).</p></div>
<div class="block mopp drugH1Div" id="F53569064"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal, hepatic, and hematologic function tests with prolonged use; observe for changes in bowel frequency.</p></div>
<div class="block pha drugH1Div" id="F226271"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane</p></div>
<div class="block phk drugH1Div" id="F226290"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: 77% to 88% (Agwuh 2006); IM: Poor, with less than 60% of dose absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely distributed to most body fluids and tissues including ascitic, synovial and pleural fluids; bronchial secretions; poor penetration into CSF </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 55% to 64% (Agwuh 2006) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 6 to 11 hours (Agwuh 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Oral: 2 to 4 hours (Agwuh 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (30%); feces (20% to 60%) (Agwuh 2006)</p></div>
<div class="block phksp drugH1Div" id="F51160036"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Because renal Cl is by glomerular filtration, excretion is significantly affected by the state of renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F226296"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Achromycin V | Ambramycin | Dumocycline | Grocycline | Ibicyn | Micycline | Servitet | Tetracycline Julphar | Tetradar | Tetrarco | Tetrex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tetraciclina omega</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Achromycin V | Mysteclin | Tetracycline | Tetrex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">A-Tetra | Aristodox | Atron | Capta | Cremycin | Decacycline | Hostacycline | Jmycin | Jp tetra | Minocin | Monatrex | Omnimycin | S-tetracycline | Taracycline | Tc | Teracilin | Tetclin | Tetrac | Tetracal | Tetracil | Tetracin | Tetracline | Tetracycline | Tetracycline-H | Tetracyn | Tetrafen | Tetragen | Tetram | Tetramed | Tetramet | Tetramycin | Tetrasina | Tetrasis | Tetraskylin | Tetrax</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aureciclina | Cloridrato de tetraciclina | Infex | Multigram | Parenzyme tetraciclina | Statinclyne | Telexin | Teraciton | Tetracaps | Tetraciclina | Tetracilil | Tetracina | Tetraclin | Tetraklin | Tetramax | Tetramed | Tetramicin | Tetraspis | Tetraxil | Tetrex | Treciclin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo-tetra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acromicina | Hostaciclina | Tetraciclina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jin jing kang | Tetracycline | Tetyacycline hydrochloride</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ambramicina | Pirocyclina | Servitet | Tetraciclina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Rimatet | Tetracyclin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Hostacyclin | Tefilin | Tetracyclin | Tetralution</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Tetraciclina | Tetrafarma</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Tetrabiotico | Tetraciclina | Tetraciclina MK | Tetrecu | Tetrex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Apo-tetra | Panmycin | Tetraciclina atb | Tetracyclin | Tetracyklin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Micycline | Tetracid | Tetracycline</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Quimpe antibiotico</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Medicyclin | Salcyclin | Tesyklin | Tetracyclin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Economycin | Steclin | Sustamycin | Tetrabid | Tetracycline berk | Tetracycline sus | Tetracyn | Totomycin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Akotid | Apo-tetra | Medocycline | Meyercycline | Qualitetra | Setrocin | Tetracin | Tetracline | Tetracycline | Tetracycline HCL</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin Wolff</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Altetra | Arsilin | Bimatra | Bufacyn | Camicycline | Centraclin | Citocycline | Combicyclin | Conmycin | Corocyclin | Dantetra | Decacycline | Decycline | Dumocycline | Enkacyclin | Erlacycline | Farsyclin | Gametra | Hitetra | Hufacyclin | Ikacyclin | Itracycline | Kalcyclin | Kemoclin | Lanacycline | Librocyn | Licoklin | Megacycline | Novabiotic | Ottocyclin | Pharocycline | Ramatetra | S-meprotetra | Sakacyclin | Samtetra | Sanlin | Scantetra | Sinacyclin | Soltralin | Steclin | Super tetra | Suprabiotic | Tetra | Tetrabiotic | Tetracycline | Tetradex | Tetramet | Tetraped | Tetrarco | Tetrin | Trifamycetin | Unicycline | Varcycline | Wiclin | Xepacyclin | Zenicyclin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Achromycin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tevacycline</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Acrocycline | Dicicyclin | Getra | Hostacycline | Larcyclin | Lupiterra | Lykaclin | Rancyclin | Rancycline | Resteclin | Subamycin | Tera-Cap | Teralin | Terapal | Tetlin | Tetrabact | Tetrac | Tetracycline | Tetracycline HCL | Tetrakem | Tetrasain | Tetrastar | Tritetra | Wocycline</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Samacycline</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ambramicina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Dumocycline | Tetradar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Brisai tx | Cytome | Junmycin v | Neocycline | Panmycin p | Tetracycline hcl organon | Tetracycline hcl taisho | Tetracycline v daiichi | Tetralysal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Biotet | Probax | Racycline | Tetracin | Tetracycline | Tetraline | Tetramed</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Teracyclin | Tetracycline</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mephicycline | Tetracycline | Tetramed</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin | Tetracyclin Wolff</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin | Tevacycline</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ambotetra | Educiclina | Erifor | Gentetril | Livitex | Oxi-t | Quimocyclar | Senociclin | Tetra atlantis | Tetra Zil | Tetraciclina Arlex | Tetraciclina gi se | Tetrerba | Tetrex | Tromicol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel tetracycline | Beatacycline | Dhatracin | Latycin | Panmycin | Pharmycin | Setrocin | Super tetra | Tetra | Tetracap | Tetracin | Tetracycla | Tetracycline | Tracyne | Triomycin | Vemyclin | Xepacycline</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Maxcyclin | Naptrene | Vadicycllin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tetracycline HCL</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin | Tetracycline HCL</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Panmycin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Hostaciclina | Orencyclin f-500 | Quemiciclina-s | Tetraciclina | Tetralan | Tetranase</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cherrylex | Dli-tetracycline hcl | Gli-tetracycline | Moncycline | Tetracycline | Traxetrine | Tricor | Unimycin | Zetra</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Dosamycin | Novocin | Tetracycline | Tetramaz</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Achromycin V | Ala-tet | Sumycin | Tetracycline HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ambramicina | Neociclina | Neociclina vitamin | Tetraciclina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Tetraciclina | Tetracilin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cyclovin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin k</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dumocycline | Tetracyclin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Beatacycline | Dhatracin | Erlimycin | Hostacycline | Latycin | Pharmycin | Super tetra | Tetracycline | Tetracycline HCL | Vemyclin | Xepacycline</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin k</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">A.d.mycin | Acnicin | Acnicin t1 | Acnicin T9 | Ambritrex | Amtrax | Bomcin | Boramycin Phosphate | Cotrex | Dada mycin | Detra | Forbiotin | Forcycline | Gano | Ganospec | Hawkmycin | Heromycin | Kentra | Lenocin | Liwinnermycin | Macmycin | Manocycline | Medicline | Moderncycline | N.L.Mycin | Naptrax | Nidacycline | Pannacycline | Pantocycline | Piccomycin | Pincycline | Pondnatrex | Servitet | Starmycin | Tc-mycin | Tephos | Tetexcin | Tetra | Tetra central | Tetracin | Tetracycline | Tetracyline hcl | Tetrafet | Tetralim | Tetraman | Tetrano | Tetraphos | Tilan mycin | Trex | Utomycin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Tetra | Tetramin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Achromycin | Bilimycin | Bocycline | Bristacycline | Diocyclin | Paromycine | Servitet | Suncycline V | Teralin | Tetocyn | Tetra | Tetracin | Tetracycline | Tetracycline HCL | Tetralow | Ttmycin | Weile | Wintel | Wintellin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Tetracyclin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agotetra | Tetracycline | Tetraren | Tetras</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Tetraciclina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ambramicina | Tetraciclina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Hostacycline | Hostacycline-p | Rolab-tetracycline | Tetrex</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Elytetra | Emcycline | Fidemycin | Tetracap | Tetrakant | Tetret</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3943679">
<a name="3943679"></a>Agha FP, Wilson JA, Nostrand TT. Medication-induced esophagitis. <i>Gastrointest Radiol</i>. 1986;11(1):7-11. doi:10.1007/BF02035023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/3943679/pubmed" id="3943679" target="_blank">3943679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16816396">
<a name="16816396"></a>Agwuh K, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. <i>J Antimicrob Chemother</i>. 2006;58(2):256-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/16816396/pubmed" id="16816396" target="_blank">16816396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-122864">
<a name="122864"></a>American Academy of Pediatrics, Committee on Drugs. Requiem for Tetracyclines. <i>Pediatrics</i>. 1975;55(1):142-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/122864/pubmed" id="122864" target="_blank">122864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23535757">
<a name="23535757"></a>Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/23535757/pubmed" id="23535757" target="_blank">23535757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6048142">
<a name="6048142"></a>Barnett CF Jr. Anaphylactoid reaction to orally administered tetracycline. <i>South Med J</i>. 1967;60(9). doi:10.1097/00007611-196709000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/6048142/pubmed" id="6048142" target="_blank">6048142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Parasites - balantidiasis (also known as Balantidium coli infection): resources for health professionals. <a href="https://www.cdc.gov/parasites/balantidium/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/balantidium/health_professionals/index.html</a>. Last reviewed May 20, 2020c. Accessed September 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated May 29, 2020a. Accessed June 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html" target="_blank">https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html</a>. Updated October 2, 2020b. Accessed May 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6786495">
<a name="6786495"></a>Channer KS, Hollanders D. Tetracycline-induced oesophageal ulceration. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6273):1359-1360. doi:10.1136/bmj.282.6273.1359-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/6786495/pubmed" id="6786495" target="_blank">6786495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi:10.1038/ajg.2016.563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825. doi:10.1111/j.1572-0241.2007.01393.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cohlan.1">
<a name="Cohlan.1"></a>Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline: a clinical and laboratory investigation of tetracycline-induced bone fluorescence. <i>AMA Am J Dis Child</i>. 1963;105:453-461.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7741368">
<a name="7741368"></a>Coronado BE, Opal SM, Yoburn DC. Antibiotic-Induced D-Lactic Acidosis. <i>Ann Intern Med</i>. 1995;122(11):839-842.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7741368/pubmed" id="7741368" target="_blank">7741368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26680308">
<a name="26680308"></a>Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?. <i>Expert Opin Drug Saf</i>. 2016;15(3):367-382. doi:10.1517/14740338.2016.1133584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/26680308/pubmed" id="26680308" target="_blank">26680308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8056550">
<a name="8056550"></a>Cuddihy J. Case Report of Benign Intra-cranial Hypertension Secondary to Tetracycline. <i>Ir Med J</i>. 1994;87(3):90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/8056550/pubmed" id="8056550" target="_blank">8056550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31360284">
<a name="31360284"></a>Del Rosso JQ, Tanghetti E, Webster G, Stein Gold L, Thiboutot D, Gallo RL. Update on the management of rosacea from the American Acne &amp; Rosacea Society (AARS). <i>J Clin Aesthet Dermatol</i>. 2019;12(6):17-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/31360284/pubmed" id="31360284" target="_blank">31360284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4879536">
<a name="4879536"></a>Demers P, Fraser D, Goldbloom RB, et al. Effects of tetracyclines on skeletal growth and dentition. A report by the Nutrition Committee of the Canadian Paediatric Society. <i>Can Med Assoc J</i>. 1968;99(17):849-854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/4879536/pubmed" id="4879536" target="_blank">4879536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3158749">
<a name="3158749"></a>Dodds PR, Chi TN. Balanitis as a fixed drug eruption to tetracycline. <i>J Urol</i>. 1985;133(6):1044-1045. doi: 10.1016/s0022-5347(17)49372-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/3158749/pubmed" id="3158749" target="_blank">3158749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;131(suppl 3):S163-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102658">
<a name="27102658"></a>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. <i>Gastroenterology</i>. 2016;151(1):51-69.e14. doi:10.1053/j.gastro.2016.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/27102658/pubmed" id="27102658" target="_blank">27102658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-130551">
<a name="130551"></a>Fox SA, Berenyi MR, Straus B. Tetracycline Toxicity Presenting as a Multisystem Disease. <i>Mt Sinai J Med</i>. 1976;43(2):129-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/130551/pubmed" id="130551" target="_blank">130551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7824136">
<a name="7824136"></a>Gardner K, Cox T, Digre KB. Idiopathic Intracranial Hypertension Associated With Tetracycline Use in Fraternal Twins: Case Reports and Review. <i>Neurology</i>. 1995;45(1):6-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7824136/pubmed" id="7824136" target="_blank">7824136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8410616">
<a name="8410616"></a>Gordon JM, Walker CB. Current Status of Systemic Antibiotic Usage in Destructive Periodontal Disease. <i>J Periodontol</i>. 1993;64(8)(suppl):760-771.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/8410616/pubmed" id="8410616" target="_blank">8410616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.1">
<a name="Graber.1"></a>Graber E. Acne vulgaris: overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hicks.1">
<a name="Hicks.1"></a>Hicks CB, Clement M. Syphilis: treatment and monitoring. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9843011">
<a name="9843011"></a>Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. <i>J Am Acad Dermatol</i>. 1998;39(6):971-974. doi:10.1016/s0190-9622(98)70272-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/9843011/pubmed" id="9843011" target="_blank">9843011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14288461">
<a name="14288461"></a>Knowles JA. Excretion of drugs in milk – a review. <i>J Pediatr</i>. 1965;66(6):1068-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/14288461/pubmed" id="14288461" target="_blank">14288461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5625449">
<a name="5625449"></a>Leblanc AL, Perry JE. Transfer of Tetracycline Across the Human Placenta. <i>Tex Rep Biol Med</i>. 1967;25(4):541-545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/5625449/pubmed" id="5625449" target="_blank">5625449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7634848">
<a name="7634848"></a>Lee AG. Pseudotumor Cerebri After Treatment With Tetracycline and Isotretinoin for Acne. <i>Cutis</i>. 1995;55(3):165-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7634848/pubmed" id="7634848" target="_blank">7634848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22171784">
<a name="22171784"></a>Lee SH, Yoon J, Kim TH, Um SH, Yoon TJ. Systemic lupus erythematosus induced by tetracycline. <i>Int J Dermatol</i>. 2013;52(2):257-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/22171784/pubmed" id="22171784" target="_blank">22171784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-424834">
<a name="424834"></a>Lehrner LM, Cooke JH, Enck RE. Tetracycline-induced aplastic anemia. <i>South Med J</i>. 1979;72(3):358-361. doi:10.1097/00007611-197903000-00037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/424834/pubmed" id="424834" target="_blank">424834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5108523">
<a name="5108523"></a>Maroon JC, Mealy J Jr. Benign Intracranial Hypertension. Sequel to Tetracycline Therapy in a Child. <i>JAMA</i>. 1979;216(9):1479-1480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/5108523/pubmed" id="5108523" target="_blank">5108523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6743732">
<a name="6743732"></a>Matsuda S. Transfer of Antibiotics Into Maternal Milk. <i>Biol Res Pregnancy Perinatol</i>. 1984;5(2):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/6743732/pubmed" id="6743732" target="_blank">6743732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19698015">
<a name="19698015"></a>Mitrano JA, Spooner LM, Belliveau P. Excretion of Antimicrobials Used to Treat Methicillin-Resistant <i>Staphylococcus aureus</i> Infections During Lactation: Safety in Breastfeeding Infants. <i>Pharmacotherapy</i>. 2009;29(9):1103-1109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/19698015/pubmed" id="19698015" target="_blank">19698015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16170138">
<a name="16170138"></a>Morrison VL, Kikkawa DO, Herndier BG. Tetracycline induced green conjunctival pigment deposits. <i>Br J Ophthalmol</i>. 2005;89(10):1372-1373. doi:10.1136/bjo.2005.069526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/16170138/pubmed" id="16170138" target="_blank">16170138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814687">
<a name="20814687"></a>Mylonas I. Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration. <i>Arch Gynecol Obstet</i>. 2011;283(1):7-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/20814687/pubmed" id="20814687" target="_blank">20814687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al; Contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26280139">
<a name="26280139"></a>Oge' LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. <i>Am Fam Physician</i>. 2015;92(3):187-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/26280139/pubmed" id="26280139" target="_blank">26280139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21352288">
<a name="21352288"></a>Ogita A, Takada K, Kawana S. Case of anaphylaxis due to tetracycline hydrochloride. <i>J Dermatol</i>. 2011;38(6):597-599. doi:10.1111/j.1346-8138.2010.01021.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/21352288/pubmed" id="21352288" target="_blank">21352288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4154770">
<a name="4154770"></a>Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. <i>Br J Dermatol</i>. 1974;91(3):319-322. doi:10.1111/j.1365-2133.1974.tb12902.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/4154770/pubmed" id="4154770" target="_blank">4154770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5903859">
<a name="5903859"></a>Pothier AJ Jr, Anderson EE. Tetracycline-induced azotemia. <i>J Urol</i>. 1966;95(1):16-18. doi:10.1016/s0022-5347(17)63401-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/5903859/pubmed" id="5903859" target="_blank">5903859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1298559">
<a name="1298559"></a>Rams TE, Slots J. Antibiotics in periodontal therapy: an update. <i>Compendium</i>. 1992;13(12):1130, 1132, 1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/1298559/pubmed" id="1298559" target="_blank">1298559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7190195">
<a name="7190195"></a>Sargent E. Tetracycline for seal finger. <i>JAMA</i>. 1980;244(5):437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7190195/pubmed" id="7190195" target="_blank">7190195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8736618">
<a name="8736618"></a>Seas C, DuPont HL, Valdez LM, Gotuzzo E. Practical guidelines for the treatment of cholera. <i>Drugs</i>. 1996;51(6):966-973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/8736618/pubmed" id="8736618" target="_blank">8736618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7876417">
<a name="7876417"></a>Seymour RA, Heasman PA. Pharmacological Control of Periodontal Disease. II. Antimicrobial Agents. <i>J Dent</i>. 1995;23(1):5-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7876417/pubmed" id="7876417" target="_blank">7876417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7706536">
<a name="7706536"></a>Seymour RA, Heasman PA. Tetracyclines in the Management of Periodontal Diseases. A Review. <i>J Clin Periodontol</i>. 1995;22(1):22-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7706536/pubmed" id="7706536" target="_blank">7706536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1749296">
<a name="1749296"></a>Smilack JD, Wilson WR, Cockerill FR 3rd. Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole. <i>Mayo Clin Proc</i>. 1991;66(12):1270-1280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/1749296/pubmed" id="1749296" target="_blank">1749296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7455865">
<a name="7455865"></a>Steinbruegge JM, Judson FN. Type I allergic reaction to orally administered tetracycline hydrochloride: a case report. <i>Sex Transm Dis</i>. 1980;7(4):193-194. doi:10.1097/00007435-198010000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7455865/pubmed" id="7455865" target="_blank">7455865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stout.1">
<a name="Stout.1"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26899755">
<a name="26899755"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/26899755/pubmed" id="26899755" target="_blank">26899755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chartwell.1">
<a name="Chartwell.1"></a>Tetracycline hydrochloride [prescribing information]. Congers, NY: Chartwell Pharmaceuticals LLC; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tetracycline.2">
<a name="Tetracycline.2"></a>Tetracycline hydrochloride capsules [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAPharma.1">
<a name="AAPharma.1"></a>Tetracycline hydrochloride capsules [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3680912">
<a name="3680912"></a>Torosis J, Vender R. Tetracycline-induced pancreatitis. <i>J Clin Gastroenterol</i>. 1987;9(5):580-581. doi:10.1097/00004836-198710000-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/3680912/pubmed" id="3680912" target="_blank">3680912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6449976">
<a name="6449976"></a>Walters BN, Gubbay SS. Tetracycline and benign intracranial hypertension: report of five cases. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6257):19-20. doi:10.1136/bmj.282.6257.19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/6449976/pubmed" id="6449976" target="_blank">6449976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7606084">
<a name="7606084"></a>Wandstrat TL, Phillips J. Pseudotumor cerebri responsive to acetazolamide. <i>Ann Pharmacother</i>. 1995;29(3):318. doi:10.1177/106002809502900319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/7606084/pubmed" id="7606084" target="_blank">7606084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14160508">
<a name="14160508"></a>Whalley PJ, Adams RH, Combes B. Tetracycline Toxicity in Pregnancy. Liver and Pancreatic Dysfunction. <i>JAMA</i>. 1964;189:357-362.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/14160508/pubmed" id="14160508" target="_blank">14160508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5487732">
<a name="5487732"></a>Whalley PJ, Martin FG, Adams RH, et al. Disposition of Tetracycline By Pregnant Women With Acute Pyelonephritis. <i>Obstet Gynecol</i>. 1970;36(6):821-826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/5487732/pubmed" id="5487732" target="_blank">5487732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5940450">
<a name="5940450"></a>Whalley PJ, Martin FG, Adams RH, et al. Tetracycline Disposition in Normal Pregnancy. <i>Obstet Gynecol</i>. 1966;28(1):103-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/5940450/pubmed" id="5940450" target="_blank">5940450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442509">
<a name="30442509"></a>Wormser GP, Wormser RP, Strle F, Myers R, Cunha BA. How safe is doxycycline for young children or for pregnant or breastfeeding women? <i>Diagn Microbiol Infect Dis</i>. 2019;93(3):238-242. doi:10.1016/j.diagmicrobio.2018.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/30442509/pubmed" id="30442509" target="_blank">30442509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2254575">
<a name="2254575"></a>Yoshikawa TT. Antimicrobial Therapy for the Elderly Patient. <i>J Am Geriatr Soc</i>. 1990;38(12):1353-1372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/2254575/pubmed" id="2254575" target="_blank">2254575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed March 3, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetracycline-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12830 Version 456.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
